Genedrive PLC Launches Genedrive® Hepatitis C test in Africa
23 Oktober 2017 - 8:00AM
RNS Non-Regulatory
TIDMGDR
Genedrive PLC
23 October 2017
genedrive plc ("genedrive" or the "Company")
genedrive launches Genedrive(R) Hepatitis C test in Africa
Genedrive(R) HCV ID Kit to be launched at IFCC WorldLab 2017
Congress
genedrive plc (AIM: GDR), the near patient molecular diagnostics
company, will launch the decentralised Hepatitis C assay,
Genedrive(R) HCV ID Kit, at the IFCC WorldLab 2017 Congress from 22
- 25 October 2017 in Durban, South Africa.
genedrive recently announced it had signed a distribution
agreement with Sysmex Europe GmbH, a subsidiary of Sysmex
Corporation, for the Genedrive(R) HCV ID Kit and the Genedrive(R)
platform in the EMEA region with an initial focus on Africa, with
the rest of the EMEA region to follow. Working together, the
companies will focus on securing the required regulatory approvals
in individual territories of Africa and genedrive anticipates
commercial traction during the 2017/2018 financial year.
The Genedrive(R) HCV assay is performed on the Genedrive(R)
instrument, an innovative and affordable system providing molecular
diagnostics at the point of need. The proprietary assay is
performed directly from a small, 30ul plasma sample and does not
require a separate viral nucleic acid extraction process. The assay
provides results within 90 minutes from lyophilised PCR reagents
packaged into a single-use, disposable cartridge.
Come and see Genedrive(R) HCV ID Kit in action at the Sysmex
booth, 30, or for further information visit www.genedrive.com.
WorldLab 2017 is a congress focused on innovative science,
evidence-based laboratory medicine and an emphasis on personalised
medicine. WorldLab 2017 is also being organized in co-operation
with the African Federation of Clinical Chemistry (AFCC).
- Ends -
For further details please contact:
genedrive plc
David Budd: CEO +44 (0)161 989 0245
Matthew Fowler: CFO
Sysmex Europe GmbH
Fernando Andreu: Senior Executive Officer +49 40 527 260
Jens Behrens: Director, Marketing Communications
Consilium Strategic Communications
Chris Gardner +44 (0)203 709 5700
Matthew Neal
Laura Thornton
genedrive@consilium-comms.com
Notes to Editors
About genedrive plc
genedrive plc is a molecular diagnostics company developing and
commercialising a low cost, rapid, versatile, simple to use and
robust point of need molecular diagnostics platform for the
diagnosis of infectious diseases and for use in patient
stratification (genotyping), pathogen detection and other
indications. The Genedrive(R) platform and MTB/RIF test have been
launched in India and a Genedrive(R) HCV test has received CE-IVD
Certification and has been launched in Africa.
Further details can be found at: www.genedriveplc.com and
www.genedrive.com
About Sysmex
Sysmex Corporation is a world leader in clinical laboratory
systemization and solutions, including laboratory diagnostics,
laboratory automation and clinical information systems. Serving
customers for more than 40 years, Sysmex focuses on technological
leadership in diagnostic science and information tools that make a
difference in the health of people worldwide. The company is also
exploring emerging opportunities in the life science field. Its
R&D efforts focus on the development of high-value-added
testing and diagnostic technologies that are innovative, original
and optimize individual health. Sysmex also seeks to leverage its
state-of-the-art technologies for cell, gene and protein analysis.
The company, headquartered in Kobe, Japan, has subsidiaries in
North America, Latin America, Europe, the Middle East, Africa,
China and Asia Pacific and employs about 8,000 employees worldwide.
Sysmex Corporation is listed in the top tier of the Tokyo Stock
Exchange. For more information about Sysmex Corporation and its
affiliate companies, please visit http://www.sysmex.co.jp/en/, and
for details on Sysmex Africa https://www.sysmex.co.za/
About Hepatitis C
Hepatitis C (HCV) is an international public health challenge,
comparable to other major communicable diseases, including HIV,
tuberculosis and malaria. It is estimated that 150-200 million
people, or approximately 3% of the world's population, are living
with chronic HCV, and more than 350,000 people die yearly from HCV
related diseases. In 2016, WHO published the first global health
sector strategy on Hepatitis with a goal of eliminating viral
hepatitis as a major public health threat by 2030. New oral,
well-tolerated treatment regimens can achieve cure rates of over
90% however access to rapid, inexpensive and accurate diagnostics
are a critical bottleneck that must be addressed to eradicate
HCV.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEASEEAEFXFFF
(END) Dow Jones Newswires
October 23, 2017 02:00 ET (06:00 GMT)
Epistem (LSE:EHP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Epistem (LSE:EHP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024